InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 23 November 2023

TOP-FLOR: This study is evaluating how safe and effective a new drug is when given in combination with targeted therapy, with or without additional immunotherapy, in people with follicular lymphomaTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab: An Umbrella Bayesian Optimal Phase II Study.

Clinical summary


Eligible participants will be randomly allocated to one of two experimental arms.

In Experimental Arm A, participants will receive the investigational drug (called BMS-986369) plus targeted therapy (rituximab). Participants in this group will receive rituximab (375mg/m2) via intravenous (IV) infusion once every 4 weeks, plus BMS-986369 (0.4mg) via oral tablet on Days 1-14 of each cycle for 8 cycles. This will be followed by rituximab (375mg/m2) via IV infusion every 12 weeks in participants with CR/PR at the end of induction.

In Experimental Arm B, participants will receive the investigational drug (BMS-986369) plus targeted therapy (rituximab) plus immunotherapy (nivolumab). Participants in this group will receive nivolumab (480mg) via IV infusion every 4 weeks, rituximab (375mg/m2) via IV infusion every 4 weeks and BMS-986369 (0.4mg) via oral tablet on Days 1-14 of each cycle for 8 cycles. This will be followed by rituximab (375mg/m2) via IV infusion every 12 weeks in participants with CR/PR at the end of induction.


This trial is treating patients with CD20 positive follicular non-Hodgkin lymphoma


Blood Cancers Haematological





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Olivia Newton-John Cancer Research Institute

Scientific Title

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab: An Umbrella Bayesian Optimal Phase II Study.



  1. Age 18+ years.
  2. Histologically proven CD20 positive Follicular non Hodgkin lymphoma (FL) grades 1-3A (i.e. classical follicular lymphoma according to the current World Health Organization classification).3
  3. No previous chemotherapy, or other investigational drug for this indication apart from focal radiotherapy.
  4. Stage II-IV disease (Ann Arbor criteria).
  5. Eastern Collaborative Oncology Group (ECOG) performance status 0 to 1 unless attributable to lymphoma, in which case patients of performance status 2 are also eligible.
  6. Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to:

a. Any nodal or extranodal tumour mass >7cm AND/OR multiple extranodal disease sites b. Involvement of at least 3 sites each with diameter >3cm c. Symptomatic splenic enlargement d. Organ involvement/compression e. Ascites or pleural effusion f. Lactate Dehydrogenase (LDH) elevated g. Presence of systemic symptoms h. Disease progression in preceding 3 months i. Evidence of marrow infiltration with marrow compromise. (e.g., Hb, WCC or plt count below lower limit of institutional normal range).

g) Adequate bone marrow function including:

  1. Haemoglobin >8.0 g/dL
  2. White cell count (WCC) ≥2000/μL
  3. Neutrophils >1.5 x 109/L
  4. Platelets >75 x 109/L at the time of study entry, unless attributed to bone marrow infiltration by lymphoma.

h) Adequate renal function with serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl) ≥ 60mL/min (using Cockcroft-Gault formula, 24hr urine collection or eGFR).

Female CrCl = (140 - age in years) x weight (kg) x 0.85 72 x serum creatinine (mg/dL)

Male CrCl = (140 - age in years) x weight (kg) x 1.00 72 x serum creatinine (mg/dL) i) Adequate hepatic function with AST/ALT ≤3x ULN and total bilirubin ≤1.5 x ULN (except subjects with Gilbert syndrome, who can have a total bilirubin ≤3 mg/dL or ≤51.3 μmol/L).

j) Adequate left ventricular ejection fraction of >45% as demonstrated on a Gated Cardiac Blood Pool Scan or echocardiogram.

k) Life expectancy > 3 months. l) Patients of childbearing potential willing to adhere to the following contraceptive precautions. Refer to the Celgene-BMS-986369/CC-99282 Pregnancy Prevention Plan (Appendix 4) for additional guidance.

  1. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.
  2. Females must not be breastfeeding.
  3. FCBP must use appropriate method(s) of contraception to avoid pregnancy for 23 weeks (30 days plus five half-lives of nivolumab) and 28 days for BMS 986369 post-treatment completion.
  4. Men who are sexually active with FCBP must use any contraceptive method with a failure rate of less than 1% per year. They must agree to adhere to contraception for a period of 90 days from the last day BMS-986369 and refrain from donating sperm.
  5. Azoospermic males and FCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described in this section.

m) Written, informed consent.


  1. Follicular large B-cell Lymphoma (Grade 3B) transformed follicular lymphoma, other indolent lymphomas.
  2. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  3. Central nervous system, meningeal involvement or spinal cord compression by lymphoma.
  4. Patients with active, known or suspected autoimmune disease. Patients with well controlled type I diabetes mellitus, coeliac disease, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, vitiligo or psoriasis not requiring systemic treatment, or other conditions not expected to recur in the absence of an external trigger are permitted to enrol.
  5. Subjects with a condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement therapy are permitted in the absence of active autoimmune disease.
  6. Past history of interstitial lung disease.
  7. Prior organ transplantation or allogeneic bone marrow transplantation.
  8. Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  9. Uncontrolled or severe cardiovascular disease (NYHA class III or IV heart failure; myocardial infarction within the last 6 months of study entry); unstable angina; unstable cardiac arrhythmias; clinically significant pericardial disease.
  10. Any other serious active disease.
  11. Any positive test result for hepatitis B or hepatitis C virus during screening indicating acute or chronic infection. Latent hepatitis B with undetectable viral load by PCR is allowable provided appropriate anti-viral prophylaxis is given as per institutional guidelines.
  12. Any positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  13. Any history of severe hypersensitivity reactions to other monoclonal antibodies.
  14. A history of allergy or intolerance (unacceptable AEs) to study drug components or Polysorbate-80-containing infusions.
  15. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.


  • You are able to swallow medication by mouth.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.